Inovio Pharmaceuticals (INO) 10-K2011 FY Annual report

Filed: 18 Mar 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adult, alive, amelioration, Anderson, article, background, benchmark, bite, born, CDC, child, Chudley, circulating, circulation, Clostridium, congenital, Cowen, CRUK, CSP, deadly, descent, difficile, divergent, DOD, donation, Ebola, factor, Fifty, Fourteen, gB, gH, gL, guinea, HAART, hanta, harder, HBcAg, highest, Houston, HVDDT, IFN, immuno, inactivated, infant, inflammatory, inter, interferon, intestinal, inventor, journal, latent, lifespan, ll, lymphocyte, Manitoba, Marburg, MD, migrate, mind, MKT, mortality, necessitated, nonstructural, nucleoside, paramount, passaged, Penn, perinatal, periphery, PhD, pig, plasma, Plasmodium, pneumonia, polyfunctional, pregnant, presence, problem, proliferation, protocol, puumala, ranked, reactivated, reinstatement, Relief, rest, retroactive, retroactively, Similarly, slowly, SOC, stark, stay, strikingly, suppressed, suppression, SW, symptomatic, Taxpayer, TIV, transplant, transplantation, TRAP, tree, trivalent, unborn, undesirable, unvaccinated, UPenn, variance, viremia, vulnerability, vulnerable, weaker, weaned, Winnipeg, younger, Zealand

Removed: acquirer, advisor, AG, aimed, allocate, Amex, assembled, auction, Bank, big, breast, cancelled, CEO, configuration, consummated, decision, deducted, deviation, dissolved, division, dominated, drew, duration, evoking, expectation, ferret, focusing, forma, fromPlasmodium, geographical, immunodeficiency, impacted, implemented, intermediate, investigatedin, leadership, leasing, LIBOR, loan, location, lung, methodology, monkey, mouse, NDA, Norway, Norwegian, partner, pathogenic, precise, projected, projection, promissory, prospectively, protected, recordkeeping, relation, reserved, retainer, retrospectively, revised, revolving, round, School, segment, served, Singapore, spend, subordinated, succeeded, tangible, Tec, thought, transfected, translated, UBS, ultimate, uncommitted, updated, USA, workforce, yearly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

INO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	March 18, 2013	/s/ J. JOSEPH KIM
		J. Joseph Kim President, Chief Executive Officer and Director (Principal Executive Officer)

Date:	March 18, 2013	/s/ PETER KIES
		Peter Kies Chief Financial Officer (Principal Financial and Accounting Officer)